• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    4/5/23 4:37:55 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRPH alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

    (AMENDMENT NO. 21)

     

    ProPhase Labs, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0005 per share

    (Title of Class of Securities)

     

    74345W 10 8

    (CUSIP Number)

     

    Herbert Kozlov, Esq.

    Wendy Grasso, Esq.

    Reed Smith LLP

    599 Lexington Avenue

    New York, New York 10022

    (212) 521-5400

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    April 5, 2023

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

     

     

     

     

    CUSIP No: 74345W 10 8

     

    1. NAME OF REPORTING PERSON:  
      Ted Karkus  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
      (See Instructions):  
      (a) ☐  
      (b) ☐  
         
    3. SEC USE ONLY  
         
    4. SOURCE OF FUNDS (See Instructions) PF
         
    5. CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e): ☐
         
    6. CITIZENSHIP OR PLACE OF ORGANIZATION United States

     

    NUMBER OF 7. SOLE VOTING POWER 3,433,750
    SHARES      
    BENEFICIALLY 8. SHARED VOTING POWER 150,000 (1)
    OWNED BY      
    EACH 9. SOLE DISPOSITIVE POWER 3,433,750
    REPORTING      
    PERSON WITH 10. SHARED DISPOSITIVE POWER 150,000 (1)

     

    11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
      3,583,750 shares of common stock  
         
    12.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

    ☐
         
    13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 20.9% (2)
         
    14. TYPE OF REPORTING PERSON (See Instructions) IN

     

     

    (1) These 150,000 shares are held by the Reporting Person’s son, who resides with him, for which he may be deemed the beneficial owner.

     

    (2) Based on 17,182,841 shares of common stock outstanding on March 31, 2023.

     

     

     

     

    Introductory Note:

     

    This Amendment No. 19 amends and supplements the Statement on Schedule 13D filed by Ted Karkus (the “Reporting Person”) on April 27, 2011 (the “Original Schedule 13D”, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed on November 15, 2011, Amendment No. 2 to the Schedule 13D filed on December 14, 2011, Amendment No. 3 to the Schedule 13D filed on May 18, 2012, Amendment No. 4 to the Schedule 13D filed on September 19, 2014, Amendment No. 5 to the Schedule 13D filed on May 27, 2015, Amendment No. 6 to the Schedule 13D filed on June 8, 2015, Amendment No. 7 to the Schedule 13D filed on January 6, 2017, Amendment No. 8 to the Schedule 13D filed on May 3, 2017, Amendment No. 9 to the Schedule 13D filed on October 3, 2017, Amendment No. 10 to the Schedule 13D filed on December 26, 2017, Amendment No. 11 to the Schedule 13D filed on February 26, 2018, Amendment No. 12 to the Schedule 13D filed on March 30, 2020, Amendment No. 13 to the Schedule 13D filed on August 17, 2020, Amendment No. 14 to the Schedule 13D filed on May 10, 2021 , Amendment No. 15 to the Schedule 13D filed on May 26, 2022, Amendment No. 16 to the Schedule 13D filed on August 11, 2022, Amendment No. 17 to the Schedule 13D filed on October 18, 2022, Amendment No. 18, to the Schedule 13D filed on January 17, 2023, Amendment No. 19 to the Schedule 13D filed on February 2, 2023, Amendment No. 20 to the Schedule 13D filed on April 4, 2023, and together with this Amendment No. 21, the “Schedule 13D”) to the extent specifically set forth below. Except as otherwise indicated, capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Schedule 13D.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended by inserting the following:

     

    On April 5, 2023, the Reporting Person gifted an aggregate of 50,000 shares to one of his sons, who resides with him.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    As of the date hereof, the Reporting Person is deemed to be the beneficial owner, within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, of 3,583,750 shares of common stock of the Issuer (including 150,000 shares held by one of the Reporting Person’s sons, who resides with him) for approximately 20.9% of the Issuer’s shares outstanding. The Reporting Person has sole voting and dispositive power with respect to 3,433,750 shares and shared voting and dispositive power with respect to the 150,000 shares held by his son who resides with him, for which he may be deemed the beneficial owner. The Reporting Person disclaims beneficial ownership of the shares held by his other son who does not reside with him.

     

    Except for the transaction described above in this Item 5, there have been no other transactions in the securities of the Issuer effected by the Reporting Person in the last 60 days.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 5, 2023

     

      /s/ Ted Karkus
      Ted Karkus

     

     

    Get the next $PRPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRPH

    DatePrice TargetRatingAnalyst
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $PRPH
    Financials

    Live finance-specific insights

    See more
    • ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

      Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

      5/20/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

      GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable. A press release detailing these results wi

      5/13/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025

      GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register usin

      3/27/25 8:27:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025

      Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProP

      5/20/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025

      GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable. A press release detailing these results wi

      5/13/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024

      Company to Accelerate BE-Smart Commercialization as a Cash-Pay Diagnostic Significantly reduces overhead, improves margins heading into Q2 2025 Company to hold a conference call Monday, March 31, 2025, at 11:00 AM EST GARDEN CITY, NY, March 31, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, today reported its financial and operational results for the full-year ended December 31, 2024 and outlined strategic corporate developments aimed at realigning the Company for sustained long-term growth, profitability, and strategic focus. Ted Karkus, CEO of ProPhase Labs, will present to

      3/31/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

      4 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/21/25 5:15:08 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hollenshead Stuart

      3 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/21/25 5:00:11 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gleckel Louis Md

      4 - ProPhase Labs, Inc. (0000868278) (Issuer)

      2/18/25 5:00:13 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Leadership Updates

    Live Leadership Updates

    See more
    • ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

      GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

      2/18/25 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Unveils Project ZenQ-AI

      Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W

      4/16/24 8:00:00 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sidus Space Appoints Bill White as Chief Financial Officer

      Sidus Space (NASDAQ:SIDU) (the "Company" or "Sidus"), a multi-faceted Space and Data-as-a-Service company, today announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024. Mr. White will oversee the Company's accounting, financial planning, capital raise, treasury, legal and regulatory functions. Mr. White has more than 30 years of experience in financial management, operations, and business development. He most recently served as Chief Financial Officer of ProPhase Labs, Inc. (NASDAQ:PRPH) and prior to ProPhase he was CFO, treasurer, and secretary of Intellicheck, Inc., a technology company listed on the NasdaqGM. Mr. White has broad domestic and int

      2/8/24 8:30:00 AM ET
      $PRPH
      $SIDU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Telecommunications Equipment
      Telecommunications

    $PRPH
    SEC Filings

    See more
    • SEC Form 10-Q filed by ProPhase Labs Inc.

      10-Q - ProPhase Labs, Inc. (0000868278) (Filer)

      5/20/25 4:06:42 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ProPhase Labs, Inc. (0000868278) (Filer)

      5/20/25 8:00:55 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by ProPhase Labs Inc.

      NT 10-Q - ProPhase Labs, Inc. (0000868278) (Filer)

      5/16/25 5:00:09 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      3/19/24 4:18:00 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/5/23 4:37:55 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

      SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

      4/4/23 4:25:33 PM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

      1/14/22 6:36:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

      HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

      12/20/21 6:25:15 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ProPhase downgraded by Dawson James

      Dawson James downgraded ProPhase from Buy to Neutral

      10/13/21 10:48:44 AM ET
      $PRPH
      Biotechnology: Pharmaceutical Preparations
      Health Care